Common and rare variants associated with kidney stones and biochemical traits. by Oddsson, Asmundur et al.
ARTICLE
Received 26 Jan 2015 | Accepted 2 Jul 2015 | Published 14 Aug 2015
Common and rare variants associated with kidney
stones and biochemical traits
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Gardar Sveinbjo¨rnsson1, Eik Haraldsdottir1, Gudmundur I. Eyjolfsson6, Olof Sigurdardottir7, Isleifur Olafsson8,
Gisli Masson1, Hilma Holm1, Daniel F. Gudbjartsson1,2, Unnur Thorsteinsdottir1,4, Olafur S. Indridason9,
Runolfur Palsson4,5,9 & Kari Stefansson1,4
Kidney stone disease is a complex disorder with a strong genetic component. We conducted
a genome-wide association study of 28.3 million sequence variants detected through
whole-genome sequencing of 2,636 Icelanders that were imputed into 5,419 kidney stone
cases, including 2,172 cases with a history of recurrent kidney stones, and 279,870 controls.
We identify sequence variants associating with kidney stones at ALPL (rs1256328[T], odds
ratio (OR)¼ 1.21, P¼ 5.8 10 10) and a suggestive association at CASR (rs7627468[A],
OR¼ 1.16, P¼ 2.0 10 8). Focusing our analysis on coding sequence variants in 63 genes
with preferential kidney expression we identify two rare missense variants SLC34A1
p.Tyr489Cys (OR¼ 2.38, P¼ 2.8 10 5) and TRPV5 p.Leu530Arg (OR¼ 3.62, P¼4.1
 10 5) associating with recurrent kidney stones. We also observe associations of the
identiﬁed kidney stone variants with biochemical traits in a large population set, indicating
potential biological mechanism.
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T
he lifetime risk of kidney stones is 8.8% in the United
States1 with an estimated recurrence rate of 14% after 1
year and 35% after 5 years2, placing a signiﬁcant burden
on the health care system1. In Iceland, the prevalence in
individuals older than 70 years is 10.1% for men and 4.2%
for women3. Kidney stones form when urine becomes
supersaturated with salts such as calcium oxalate or calcium
phosphate and when urine concentrations of natural inhibitors of
stone formation such as citrate, magnesium, pyrophosphate,
uromodulin and osteopontin are low4,5. Calcium oxalate and
calcium phosphate are the most common (B80%) constituents
of kidney stones5. The mechanism of stone formation involves
both environmental factors such as diet6 and genetic traits.
Individuals with a family history of kidney stones are at a greater
risk than others of developing the condition. Recent studies
estimate that up to 65% of kidney stone formers have a family
history of kidney stones7–9 and both twin10 and genealogy11
studies have reported strong heritability of kidney stone disease.
Candidate gene association studies have attempted to assess the
role of several genes involved in calcium homeostasis on kidney
stone formation12. These studies have been limited by sample
size, the results are conﬂicting and they do not consider a broad
spectrum of sequence variants.
We previously published a genome-wide association study
(GWAS) of kidney stone disease, testing a total of 303,120
variants in 1,507 cases and 34,033 controls from Iceland13.
Following replication in additional cases and controls from
Iceland and the Netherlands, we reported a genome-wide
signiﬁcant association of the CLDN14 locus, encoding the tight
junction protein Claudin-14, on 21q22.13 with kidney stones
(rs219780[C], allele frequency¼ 79.20%, odds ratio (OR)¼ 1.25,
P¼ 4.0 10 12). A GWAS in the Japanese population
involving 904 cases and 7,471 controls reported three loci
associated with kidney stones following replication in additional
cases and controls, RGS14-SLC34A1, encoding regulator of
G-protein signalling 14 and the Na/Pi co-transporter solute
carrier family 34 member 1, on 5q35.3 (rs11746443[A],
OR¼ 1.19, P¼ 8.5 10 2), INMT-FAM188B-AQP1, a locus
including the gene encoding aquaporin 1, on 7p14.3
(rs1000597[C], OR¼ 1.22, P¼ 2.2 10 14), and DGKH,
encoding diacylglycerol kinase eta, on 13q14.1 (rs4142110[C],
OR¼ 1.14, P¼ 4.6 10 9)14.
In the current study, we have substantially increased the
sample size from our previous study13 (N cases¼ 5,419;
N controls¼ 279,870). We were also able to increase the
number of sequence variants tested by performing GWAS on
imputed genotypes of sequence variants identiﬁed through
whole-genome sequencing of 2,636 Icelanders, yielding a more
extensive coverage of the genome. In addition to discovering
associations with kidney stones, we assessed the association
of these variants to 13 biochemical traits involved in
calcium–phosphate metabolism, purine metabolism, kidney
function, acid–base and ion homeostasis in a large population set.
Results
Main ﬁndings. In our previous work, we sequenced the whole
genomes of 2,636 Icelanders15,16 (median sequencing depth of
23 ) yielding 28.3 million sequence variants. Subsequently, we
imputed these variants assisted by long-range haplotype phasing
into 98,721 Icelanders genotyped with Illumina SNP chips17,18.
Using Icelandic genealogy data, we also calculated genotype
probabilities of untyped close relatives of chip-typed
individuals19. We examined the association between sequence
variants and kidney stones in 5,419 Icelandic kidney stone
formers3 (2,979 chip-typed and 2,440 chip-typed ﬁrst- or second-
degree relatives) including 2,172 recurrent kidney stone formers
(see Methods for deﬁnition) and 279,870 controls (88,266 chip-
typed and 191,604 chip-typed ﬁrst- or second-degree relatives).
We assessed the association of kidney stone associated
sequence variants with biochemical parameters involved in
calcium–phosphate metabolism (serum calcium, N¼ 114,489;
serum ionized calcium, N¼ 18,516; serum phosphate, N¼ 51,056;
parathyroid hormone (PTH), N¼ 15,541; 25-hydroxy vitamin D,
N¼ 7,544; alkaline phosphatase (ALP), N¼ 126,060), purine
metabolism (serum uric acid, N¼ 56,025), acid–base homeostasis
(serum bicarbonate (N¼ 44,511), kidney function (serum
creatinine, N¼ 195,933) and ion homeostasis (serum chloride,
N¼ 92,938; serum magnesium, N¼ 37,188; serum potassium,
N¼ 201,720; serum sodium, N¼ 198,119).
In this study, we found variants at three loci associated with
kidney stones at a genome-wide signiﬁcance level (0.05/28.3
million¼ 1.8 10 9) and one additional locus with suggestive
association (Fig. 1; Table 1). At these loci, we also observed
genome-wide signiﬁcant associations with serum calcium,
phosphate, PTH and ALP that do not in all cases correlate with
the corresponding kidney stone association signal. Focusing on
coding variants in genes with preferential renal expression, we
also found two rare coding variants associating with kidney
stones and recurrent stone formation.
Variants at ALPL. We observe a genome-wide signiﬁcant signal
with two fully correlated markers associating with kidney
stones in ALPL at 1p36.12, represented by rs1256328 [T] (minor
allele frequency (MAF)¼ 17.79%, OR¼ 1.21, P¼ 5.8 10 10)
(Fig. 2; Table 1; Supplementary Table 1). A missense variant in
ALPL (rs34605986 [A], MAF¼ 15.21%, NP_000469.3:p.
Val522Ala) that correlates with rs1256328 (r2¼ 0.73) also
associates with kidney stones (OR¼ 1.19, P¼ 8.9 10 8)
(Supplementary Table 1). When considering the 3,119 variants
located within the linkage disequilibrium (LD) block containing
rs1256328 no variants remained signiﬁcant after adjusting for it
(P40.05/1,625¼ 3.1 10 5) (Fig. 2; Supplementary Table 1).
ALPL encodes a tissue nonspeciﬁc ALP. The sequence variant
rs1256328 [T] and the correlated missense variant ALPL
p.Val522Ala have a signiﬁcant association with increased serum
ALP levels in the general population (effect 47.8 s.d.%,
Po2.2 10 32) (Table 2). To attempt replication, we directly
genotyped the missense variant ALPL p.Val522Ala in a Danish
population set (N¼ 5,822, MAFDenmark¼ 17.53%). We replicated
the association (P¼ 3.0 10 4) with an effect¼ 10.73 s.d.%.
Combined analysis of discovery and replication sets yielded a
P¼ 3.5 10 35 and an effect¼ 8.00 s.d.% with no heterogeneity
between the populations (P¼ 0.38). This is consistent with a
previous functional study where a mutated version of ALPL
carrying p.Val522Ala showed increased enzyme activity in a
cell-based assay20. Within ALPL, we also detect a low-frequency
missense variant (rs149344982[A], MAF¼ 1.42%, NP_000469.3:
p.Arg152His), which associates strongly with reduced serum ALP
levels (effect¼  45.9 s.d.%, P¼ 9.84 10 105) and suggestively
with reduced risk of kidney stones (OR¼ 0.742, P¼ 8.1 10 3)
(Supplementary Table 2). ALPL p.Arg152His has little
correlation with the more common ALPL variants rs1256328
and p.Val522Ala (r2o0.0040) (Supplementary Table 3). This
ﬁnding is in line with the effect of several rare loss-of-function
variants in ALPL that have been reported in patients with
hypophosphatasia (OMIM:146300), a syndrome characterized
by decreased levels of ALP and elevated urine pyrophosphate 21,
a known inhibitor of kidney stone formation4. ALPL is expressed
in the proximal tubules of the kidney21 and hydrolyses
pyrophosphate to free phosphate, where it may promote the
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formation of kidney stones4. Our results, for variants in ALPL
that either increase or decrease ALP levels, suggest that the effect
of ALPL on extracellular pyrophosphate metabolism can
inﬂuence kidney stone formation.
The most signiﬁcant association with serum phosphate levels
in the Icelandic population is observed at the ALPL locus,
represented by rs12132412[G] (MAF¼ 34.85%, effect¼ 5.0 s.d.%,
P¼ 1.8 10 19) (Supplementary Table 2). This variant remains
signiﬁcant (adjusted P¼ 1.7 10 6, adjusted effect¼ 3.9 s.d.%)
after adjusting for the correlated rs1697421 (r2¼ 0.54), which has
been reported to associate with serum phosphate levels22.
Notably, rs12132412[G] also associates with ALP levels
(effect¼  6.5 s.d.%, P¼ 1.1 10 34) and is correlated
(r2¼ 0.41) with rs1976403, which has been associated with
ALP levels23 (Supplementary Table 3). In the Icelandic
population, the reported sequence variant rs1976403[C]
associates signiﬁcantly with both ALP (effect¼ 10.4 s.d.%,
P¼ 4.3 10 93) and serum phosphate levels (effect¼  3.7
s.d.%, P ¼ 5.2 10 12) (Supplementary Table 2). Interestingly,
rs12132412 and rs1976403 have little correlation with rs1256328
and ALPL p.Arg152His that show association with kidney stones
and demonstrate signiﬁcant associasion with ALP at the ALPL
locus (r2o0.0062) (Supplementary Table 2; Supplementary
Table 4). Similarly, rs1256328 and ALPL p.Arg152His do not
associate with serum phosphate levels (effect¼  0.3 s.d.%,
P¼ 0.71 and effect¼ 3.7 s.d.%, P¼ 0.1, respectively)
(Supplementary Table 2).
In summary, we report three uncorrelated (r2o0.0062 for
all pairs) genome-wide signiﬁcant signals at the ALPL locus
associating with ALP and kidney stones (rs1256328 ), ALP and
serum phosphate (rs12132412 and rs1976403) and ALP
(rs149344982).
Variants at SLC34A1. On 5q35.3 at the SLC34A1 locus, encoding
the Na/Pi co-transporter SLC34A1, we replicate with an effect
size similar to the replicated one a common kidney stone
association signal previously reported in an Asian population14
(Supplementary Table 5). The strongest marker in our data
rs12654812[A] (MAF¼ 41.84%) associates with kidney stones
with an OR¼ 1.18 and P¼ 5.7 10 11 (Fig. 1; Table 1) and
correlates with the previously reported marker (r2¼ 0.68)
(Supplementary Table 5). Nine variants located in or near
SLC34A1 show genome-wide signiﬁcant association with kidney
Table 1 | Summary information for the lead regional sequence variants associating with kidney stone.
SNP ID Position (Hg18) A MAF (%) ice/1Keu Locus Kidney stones Recurrent kidney
stones
Mechanism
P OR P OR
rs199565725 chr21:36757108 A/AAC 23.68/23.20 CLDN14 4.7 10 13 0.81 3.5 10 9 0.77 Cell–cell adhesion
rs12654812 chr5:176726797 A/G 41.84/34.78 SLC34A1 5.7 10 11 1.18 4.4 10 7 1.21 Na/Pi co-transporter
rs1256328 chr1:21769354 T/C 17.79/17.32 ALPL 5.8 10 10 1.21 4.0 10 6 1.23 Alkaline phosphatase
rs7627468 chr3:123428789 A/G 26.80/24.02 CASR 2.0 108 1.16 4.1 10 5 1.18 Ca-sensing G-protein-
coupled receptor
A, allele (minor/major); MAF, minor allele frequency (ice, Iceland; 1Keu, 1000 genomes European Americans); OR, odds ratio.
Reported are the three genome-wide signiﬁcant (Po1.8 109) sequence variants (rs199565725, rs12654812 and rs1256328) and in addition one suggestive sequence variant (rs7627468) associating
with kidney stone in Iceland.
Kidney stones
20
15
10
5
0
CASR
ALPL
RGS14-SLC34A1
CLDN14
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 18 20 22
Chromosome
–
Lo
g1
0(P
)
Figure 1 | Manhattan plot showing individual P values against genomic positions for associations with kidney stones Genome-wide association
analysis of kidney stones yielded four loci (CLDN14, RGS14-SLC34A1, ALPL and CASR) that inﬂuence kidney stones in Iceland (cases: 5,419, controlls:
279,870 ). Logistic regression was used for association testing between sequence variants and disease, treating disease status as the response and
genotype counts as covariates. For the plot, the –log10 P values (y axis) of sequence variants are shown according to thier chromosomal position (x axis).
The red line indicates the threshold for genome-wide statistical signiﬁcance, which takes into account the effects of multiple testing (P¼0.05/28.3
million¼ 1.8 109).
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stones and correlate with the index variant rs12654812 (r240.63)
(Fig. 2; Supplementary Table 6). In addition, we demonstrate
that rs12654812[A] associates signiﬁcantly with decreased serum
PTH levels (effect¼  5.9 s.d.%, P¼ 2.3 10 9) and decreased
serum phosphate (effect¼  4.2 s.d.%, P ¼ 1.1 10 14)
(Table 2). The sequence variant rs12654812 has also been
reported by us and others to associate with kidney function-
related traits24,25. To search for additional signals at this locus
after adjusting for the index variant rs12654812, we performed
conditional analysis including all variants located within the
LD block containing rs12654812. We identiﬁed three strongly
correlated (r240.90) rare variants, chr5:176686425[G], chr5:
176688995[T] and chr5:176757439[G] (hg18) (MAFo0.50 %),
that remained signiﬁcant given the number of tests performed
after adjusting for rs12654812 (Po2.0 10 5¼ 0.05/2,516). One
is a missense variant in SLC34A1 (chr5:176757439[G] (NCBI36/
hg18), NP_003043.3:p.Tyr489Cys, MAF¼ 0.46 %) that was
observed only once among 61,486 exomes in the Exome
Aggregation Consortium (ExAC: http://exac.broadinstitute.org)
database26 (N samples¼ 2,535). SLC34A1 p.Tyr489Cys shows
the best association of all coding variants (N¼ 24) with kidney
stone disease (adjusted OR¼ 1.93, adjusted P¼ 1.4 10 5) and
recurrent stone formation (adjusted OR¼ 2.58, adjusted
P¼ 4.3 10 6) (Table 3) in SLC34A1 and the nine adjacent
genes that reside within the same LD block (Fig. 2).
The p.Tyr489Cys variant is located in the Na/Pi co-transporter
domain27 (amino acids 368–504, see Supplementary Fig. 1)
at a highly conserved position (GERP28¼ 5.03) and is
predicted to be pathogenic (PolyPhen29¼ probably damaging
and SIFT30¼ deleterious). Interestingly, p.Tyr489Cys has been
reported to associate with increased serum creatinine such as
the common kidney stone risk variant rs12654812 [A]25. In our
data, p.Tyr489Cys also associates with decreased PTH levels,
similar to rs12654812[A] (Table 2; Supplementary Table 7).
The association data presented here point to SLC34A1 as
the kidney stone target at this locus. In support of this
hypothesis, several studies demonstrate that rare variants
in SLC34A1 are linked to hypophosphatemic nephrolithiasis/
osteoporosis (OMIM:612286) and that SLC34A1 is the only
gene at the locus that shows tissue-speciﬁc gene expression in
kidney31 . Furthermore, the observed changes in biochemical
traits reﬂect the function of SLC34A1 as a phosphate transporter.
The kidney is the main regulatory organ of phosphate
homeostasis and serum phosphate levels are reﬂected by a
change in phosphate reabsorption. SLC34A1 is expressed in
the brush border membrane of proximal tubular cells, where
the bulk of phosphate reabsorption takes place, and appears to
be responsible for B70% of total phosphate transport based on
mouse models in which Slc34a1 has been knocked out32–34. The
reduction in serum PTH levels associated with the kidney stone
variants likely results from a decrease in serum phosphate levels
caused by diminished renal reabsorption as a consequence of the
negative feedback loop that maintains serum phosphate levels.
Variants at CLDN14. We previously reported a genome-wide
signiﬁcant association at the CLDN14 locus on 21q22.13 with
kidney stones represented by rs219780 (ref. 13). In the current
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Figure 2 | Locus plots corresponding to genome-wide signiﬁcant and suggestive loci associating with kidney stone Logistic regression was used for
association testing between sequence variants and disease, treating disease status as the response and genotype counts as covariates (a–d) For each
plot, the  log10 P values, derived by logistic regression, (y axis) for the sequence variants are shown according to their chromosomal positions (x axis).
The signiﬁcant loci are at 1p36 (a), 5q35 (c), 21q22 (d) and suggestive locus at 3q21 (b). Orange sequence variant colour represent association values
after adjusting for the leading variant. Estimated recombination rates are shown as pink lines and the genomic locations of genes at the locus are depicted
in blue. The red solid line indicates the threshold for genome-wide statistical signiﬁcance, which takes into account the effects of multiple testing
(P¼0.05/28.3 million¼ 1.8 109). The red broken line indicates the signiﬁcance threshold for claiming independence of the index varaint based on the
number variants located within the LD block containing the index variant at each locus (ALPL; 0.05/1,625¼ 3.1 10 5, CASR; 0.05/1,078¼4.6 10 5,
SLC34A1; 0.05/2,516¼ 2.0 10 5, CLDN14; 0.05/1,993¼ 2.5 10 5).
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analysis, a total of 31 correlated variants at the locus reach
genome-wide signiﬁcance, including six variants for recurrent
kidney stones (Fig. 1; Fig. 2; Supplementary Table 8).
The strongest signal associating with kidney stones is a two
base pair deletion in intron 1 of CLDN14 rs199565725[delAC]
(MAF¼ 23.68%, OR¼ 0.81, P¼ 4.7 10 13) (Table 1)
correlating with the previously reported sequence variant
rs219780[T] (r2¼ 0.82, OR¼ 0.81, P¼ 2.6 10 11). We do not
observe a signiﬁcant residual signal when adjusting the
association of rs199565725 with kidney stones for rs219780
(adjusted P¼ 0.086). When considering the number of variants
in the LD block containing rs199565725 no variants
remained signiﬁcant after adjusting for this variant (P40.05/
1,993¼ 2.5 10 5).
CLDN14 is a member of the claudin superfamily of proteins
that regulate paracellular transport of ions and small solutes at
epithelial tight junctions. We demonstrate that the sequence
variant rs199565725[delAC] also associates with increased serum
magnesium (effect¼ 4.0 s.d.%, P¼ 2.0 10 7), decreased serum
potassium (effect¼  1.2 s.d.%, P¼ 8.2 10 4) and decreased
PTH (effect¼  4.5 s.d.%, P¼ 1.1 10 4) (Table 2). Interest-
ingly, Cldn14 knockout mice have signiﬁcantly higher serum
magnesium levels than wild-type animals when kept on a high-
calcium diet35. This might indicate that rs199565725[delAC]
mediates a decrease of CLDN14 gene function. Consistent with
our previous study, rs199565725[delAC] shows a nominal
association with bone mineral density (Supplementary Table 9).
Variants at CASR. After the three genome-wide signiﬁcant loci
for kidney stones, we observe a suggestive association of
rs7627468[A] in the ﬁrst intron of CASR at 3q21.1 encoding
the calcium-sensing receptor (MAF¼ 26.80%; OR¼ 1.16,
P¼ 2.0 10 8) (Table 1; Fig. 1). CASR is a G-protein-coupled
receptor expressed on the apical surface of the proximal tubule36
that plays a key role in renal control of calcium homeostasis37 and
has long been considered a candidate gene for kidney stones38,39.
A total of 58 variants, strongly correlated with rs7627468
(r240.95) and located within intron 1 of CASR, associate with
kidney stones (Fig. 2; Supplementary Table 10). A non-signiﬁcant
Table 2 | Kidney stone associated biochemical traits.
Trait* N (KS cases) CLDN14 rs199565725[T] SLC34A1 rs12654812[A] ALPLrs1256328[T] CASR rs7627468[A]
P Effect
(s.d.%)
P Effect
(s.d.%)
P Effect(s.d.%) P Effect
(s.d.%)
Calcium–phosphate metabolism
ALP 126,060 (3,869) 0.30 0.6 0.037 1.1 2.2 10 32 7.8 0.92 0.1
PTH 15,541 (1,003) 1.1 104 4.5 2.3 109  5.9 0.62 0.6 0.13 1.7
25-OH VD 7,544 (377) 0.72 0.7 0.87 0.3 0.38  1.7 7.5 10 3 4.6
Purine metabolism
Uric Acid 56,025 (2,667) 0.20  1.0 0.090 1.1 0.56 0.5 0.59 0.4
Acid–base homeostasis
Bicarbonate 44,511 (1,576) 0.60 0.4 0.15 0.1 0.50 0.6 0.61 0.4
Kidney function
Creatinine 195,933 (4,911) 0.17 0.6 5.4 10 8 0.2 0.95 0.1 0.45 0.3
Ion homeostasis
Calcium 114,489 (3,842) 0.34 0.5 0.012 1.1 0.79 0.1 1.1 10 3 1.6
Calcium
ionized
18,516 (1,129) 0.57 0.5 0.026 1.8 0.63 0.5 6.0 10 3 2.5
Chloride 92,938 (3,228) 0.61 0.3 0.81 0.1 0.09 0.1 0.26 0.6
Magnesium 37,188 (1,472) 2.0 10 7 4.0 0.27 0.7 0.53 0.5 0.36 0.7
Phosphate 51,056 (2,228) 0.11 1.0 1.1 10 14 4.2 0.71 0.3 0.01  1.5
Potassium 201,720 (4,980) 8.2 104  1.2 0.65 0.1 0.80 0.1 0.05 0.7
Sodium 198,119 (4,951) 0.39 0.3 0.019 0.8 0.41 0.3 0.11 0.6
ALP, alkaline phosphatase; PTH, parathyroid hormone, 25-OH VD, 25-hydroxy vitamin D; N, number of individuals with genotype information with quantitative traits measurements
Association of genome-wide signiﬁcant and suggestive kidney stone sequence variants with biochemical traits involved in calcium–phosphate metabolism, purine metabolism, kidney function, acid–base
and ion homeostasis.
Underlined are P values reaching a signiﬁcant threshold for the number of tests performed (0.05/52¼ 9.6 104). The number of kidney stone cases in each group is indicated within brackets.
*All measurements are obtained from serum.
Table 3 | Summary information for coding sequence variants in genes with speciﬁc or enriched expression in the kidney
associating with kidney stone.
Position (Hg18) A MAF (%) Gene HGVSp Kidney stones Recurrent kidney stones Mechanism
P* OR P* OR
chr5:176757439 G/A 0.46 SLC34A1 NP_003043.3:p.Tyr489Cys 8.5 10 5 1.82 2.8 10 5 2.38 Na/Pi co-transporter
chr7:142319969 C/A 0.13 TRPV5 NP_062815.2:p.Leu530Arg 2.3 10 3 2.17 4.1 10 5 3.62 Ca channel
OR, odds ratio
*Genes with speciﬁc or enriched kidney expression: N¼63. Coding variants with a MAF40.01% within these genes: N¼ 220, signiﬁcance threshold for the number of test performed:
0.05/220¼ 2.3 104.
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trend was observed for rs7627468[A] with increased serum
calcium (effect¼ 1.6 s.d.%, P¼ 1.1 10 3), increased
ionized calcium (effect¼ 2.5 s.d.%, P¼ 6.0 10 3) and with
decreased 25-hydroxy vitamin D levels (effect¼  4.6 s.d.%,
P¼ 7.5 10 3) (Table 2). We note that rs7627468 is not
correlated with rs73186030, located 8-kb downstream of
the CASR gene, (r2¼ 0.0073) that is the most signiﬁcant marker
for serum calcium in the Icelandic population (effect¼ 12.3 s.d.%,
P ¼ 2.0 10 61) and is strongly correlated with rs1801725
(NP_000379.2:p.Ala986Ser) (r2¼ 0.97), which has been
associated with serum calcium40,41. The sequence variant
rs73186030 does not associate with kidney stones (OR¼ 0.96,
P¼ 0.33) and this association remains unaffected after
adjusted for the kidney stone variant rs7627468 (Supplementary
Table 11). Conversely, when adjusted for the serum calcium
variant rs73186030, the association of the kidney stone
variant rs7627468[A] with serum calcium (adjusted effect¼ 2.2
s.d.%, adjusted P¼ 3.9 10 6) and ionized serum calcium
strengthens (adjusted effect¼ 3.1 s.d.%, adjusted P¼ 7.0
10 4) (Supplementary Table 11).
In summary, we observe two uncorrelated signals (r2¼ 0.0073)
at the CASR locus, one for serum calcium only (rs73186030) and
one mainly for kidney stones (rs7627468). Taken together, this
suggests that the effect of CASR on kidney stones is complex. The
sequence variant rs73186030, which has a strong effect on serum
calcium, does not associate with kidney stones. The kidney stone
variant rs7627468 and other linked variants associated with
kidney stones are located within intron 1 of CASR that entails a
regulatory region42.
Rare coding variant in TRPV5. We used a recent source of data
on tissue-enriched gene expression in an attempt to analyse
coding variants in genes with preferential kidney expression31.
We tested a total of 220 coding variants in 63 genes, showing
tissue-speciﬁc or enriched expression in the kidney, for
association with kidney stones and recurrent kidney stones. In
addition to SLC34A1 p.Tyr489Cys, we found a rare missense
variant in TRPV5 (NP_062815.2:p.Leu530Arg (MAF¼ 0.13 %)
associating signiﬁcantly with recurrent kidney stones (OR¼ 3.62,
P¼ 4.1 10 5o0.05/220¼ 2.3 10 4) (Table 3). The TRPV5
p.Leu530Arg variant was observed only once in the ExAC
database (samples N¼ 61,486)26. The variant is at a highly
conserved position (GERP28¼ 5.8) and is predicted to be
damaging by two different algorithms (PolyPhen29¼ probably
damaging and SIFT30¼ deleterious). TRPV5 is a highly selective
epithelial calcium channel and the mutation lies within the
pore-forming region of the protein (amino acids 527–538)43
(Fig. 3; Supplementary Fig. 1). The change in coding sequence
results in substitution of the hydrophobic amino acid leucine
with a positively charged arginine at position 530 (Fig. 3).
The introduction of a positive charge into the hydrophobic
pore-forming region of TRPV5 is expected to interfere with the
diffusion of positively charged calcium ions across the channel.
TRPV5 is expressed at the apical membrane of distal renal tubule
epithelial cells that mediates calcium transport in the kidney and
constitutes the rate-limiting step of active calcium reabsorption44.
Trpv5 knockout mice and mice carrying a point mutation in
Trpv5 exhibit renal calcium wasting resulting in severe
hypercalciuria45,46. TRPV5 has been suggested to play a role in
hypercalciuric disorders but candidate gene studies have so far
failed to demonstrate an association44,47,48.
Variant in APRT and recessive mode of inheritance. We note
that we observe a strong association of a missense variant in the
APRT gene encoding adenine phosphoribosyltransferase
(rs104894506[A], NP_000476.1:p.Asp65Val, MAF¼ 1.26%)
with kidney stones under the recessive model (OR¼ 31.97,
P¼ 6.83 10 10). This mutation has previously been reported
to cause adenine phosphoribosyltransferase deﬁciency under a
recessive mode of inheritance (OMIM:614723) with kidney stones
as a hallmark clinical manifestation in Iceland49,50. Consistent
with this observation, we do not observe a signiﬁcant association
of rs104894506[A] with kidney stones under the additive
model (OR¼ 1.01, P¼ 0.93). No other variant showed a
genome-wide signiﬁcant association with kidney stones under
the recessive model.
Replication of Asian variants. A GWAS in Asians reported three
loci associating with kidney stones14. In addition to the variants at
the SLC34A1 locus mentioned above, we were able to replicate
variants at the INMT-FAM188B-AQP1 locus (Po3.3 10 3,
OR¼ 1.16–1.21) (Supplementary Table 6).
Discussion
We performed a GWAS of 28.3 million variants discovered
through sequencing and observed four common sequence
variants associating with the risk of kidney stones at ALPL,
SLC34A1, CLDN14 and CASR. We replicate the association of the
variant at SLC34A1 reported in Asians14 and we previously
reported13 the signal corresponding to the association of the
variant at CLDN14. In addition to the classic GWAS approach,
we used a recent resource31 on tissue-speciﬁc expression together
with the ability to detect and impute rare variants to analyse
coding changes in genes with enriched expression in the kidney.
Among those, we found rare missense variants at highly
conserved sites in SLC34A1 and TRPV5 associating strongly
with risk of kidney stones and recurrent kidney stones. The
identiﬁcation of a rare missense variant in SLC34A1, independent
of common variants in the region, points to SLC34A1 as the
causative gene for both signals. Interestingly, the calcium channel
TRPV5 has been the focus of several studies suggesting a role in
kidney stone formation12. Sequencing a large number of
individuals (N¼ 2,636) in a founder population allowed us to
detect the TRPV5 p.Leu539Arg variant (MAF¼ 0.13%). This
variant is essentially absent from other sequenced populations
and is located at an extremely conserved site in the pore-forming
region of the protein, making it likely to be the causal variant
explaining the association with recurrent kidney stones. The total
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Figure 3 | Schematic illustration of the topology of the TRPV5 protein
The TRPV5 p.L530R mutation occurs within the pore-forming region
(amino acids 527–538) of the ion transport domain (amino acids 389–578)
of TRPV5 replacing a hydrophobic with a basic amino acid. Acidic and basic
amino acids as red and blue, respectively.
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proportion of sibling recurrence risk for kidney stones explained
by the identiﬁed sequence variants is 4.81% (Supplementary
Table 12).
Two of the identiﬁed genes are involved in phosphate
homeostasis (ALPL4 and SLC34A1 (refs 12)) and the other
three genes play a key role in renal handling of calcium (CLDN14
and CASR, TRPV5)12. We screened the kidney stones associated
variants for their association to serum level of biochemical
traits and detected association of variants at ALPL with ALP,
SLC34A1 with PTH, and creatinine, phosphate and CLDN14
with PTH, magnesium and potassium. We also observed
uncorrelated genome-wide signiﬁcant association of variants at
these loci that inﬂuence serum levels of biochemical traits but
do not associate with the disease in all cases. This implies that
the risk is not mediated solely through the serum levels of the
biochemical traits.
The observation of three uncorrelated signals at ALPL
associating with ALP levels which do not predict their
associations with serum phosphate and kidney stones is
noteworthy. This is an example of allelic heterogeneity that is
particularly interesting in the context of the relationship between
metabolic bone disease and kidney stones.
A similar pattern is observed at CASR where we observe two
uncorrelated signals, one located in intron 1 of the CASR
gene associating with kidney stones and the other at the 30-end of
the gene associating strongly with serum calcium but not with
kidney stones. This observed allelic heterogeneity might reﬂect
differences in the function of CASR in the kidney on one hand
and the parathyroid gland on the other. Variations in intron 1
might speciﬁcally inﬂuence gene expression in the kidney
inﬂuencing the ability of CASR to respond to extracellular
calcium and in this way increase the risk of kidney stone
formation51.
In summary, the genetic associations presented emphasize the
role of sequence variants in genes involved in calcium–phosphate
homeostasis in kidney stone disease. The pathophysiology
underlying these associations requires further study.
Methods
The Icelandic study population. This study is based on whole-genome sequence
data from the whole blood of 2,636 Icelanders participating in various disease
projects at deCODE genetics15,16 (Supplementary Tables 13 and 14) (European
Variant Archive: PRJEB8636). In addition, a total of 104,220 Icelanders have
been genotyped using Illumina SNP chips15,16 (Supplementary Table 15) and
genotype probabilites for untyped relatives has been calculated based on Icelandic
genealogy15,16.
All participating individuals, or their guardians, gave their informed consent
before blood samples were drawn. The family history of participants donating
blood was incorporated into the study by including the phenotypes of ﬁrst- and
second-degree relatives and integrating over their possible genotypes.
All sample identiﬁers were encrypted in accordance with the regulations of the
Icelandic Data Protection Authority. Approval for these studies was provided by
the National Bioethics Committee and the Icelandic Data Protection Authority.
Kidney stone study population. To identify kidney stone cases, we searched for
patients with International Classiﬁcation of Diseases (ICD) codes, radiology
diagnosis codes and surgical procedure codes indicative of kidney stones3 at
Landspitali—The National University Hospital of Iceland in Reykjavik (LUH), a
community hospital for half of Iceland’s population and a tertiary care centre for
the whole nation; Akureyri Hospital in North Iceland, the largest hospital outside
the Reykjavik area; and Domus Radiology in Reykjavik, the largest privately
operated medical imaging clinic in the country. A thorough medical record review
was conducted for all patients identiﬁed to conﬁrm the diagnosis of kidney stones.
Patients with calciﬁcations other than kidney stones and asymptomatic kidney
stones were excluded from the study. A total of 5,419 kidney stone cases were
included in the association analysis; 2,979 of these were genotyped using various
Illumina chips and imputed using long-range phased haplotypes, and genotype
probabilities for 2,440 were imputed on the basis of information from genotyped
close relatives15,16. Among the kidney stone cases were 2,172 recurrent kidney
stone formers. A recurrent episode was deﬁned as the development of a new stone
occurring at least 6 months following the ﬁrst stone event. Controls comprised
individuals recruited through different genetic research projects at deCODE.
Individuals in the kidney stone cohort were excluded from the control group.
Of the controls, 88,266 were genotyped by chip, and 191,604 were imputed on the
basis of the genotypes of close relatives15,16. The total number of controls was
279,870.
Quantitative trait measurements. We studied a sample of Icelanders with
biological markers measured at three different laboratories: the laboratory of the
LUH, the Icelandic Medical Center (Laeknasetrid) Laboratory in Mjodd (RAM)
and Akureyri Hospital (FSA). Here we use measurements of serum calcium
(N¼ 114,489, geometric mean (GM)¼ 2.3), ionized serum calcium (N¼ 18,516,
GM¼ 1.8), PTH (N¼ 15,541, GM¼ 2.0), 25-hydroxy vitamin D (N¼ 7,544,
GM¼ 1.35), serum phosphate (N¼ 51,056, GM¼ 1.8), ALP (N¼ 126,060,
GM¼ 2.6), bicarbonate (N¼ 44,511, GM¼ 1.7), chloride (N¼ 92,938, GM¼ 2.2),
potassium (N¼ 201,720, GM¼ 4.2), sodium (N¼ 198,119, GM¼ 4.1) and uric
acid (N¼ 56,025, GM¼ 1.9). The arithmetic mean of the quantile–quantile
standardized trait values, adjusted for sex and age at the time of measurement for
each individual, was used in the analysis.
A Danish sample set was included in the study involving measurement of ALP
of healthy individuals from the Inter99 study52. The study was approved by the
Regional Scientiﬁc Ethical Committees for Southern Denmark and the Capital
Region of Denmark. Informed consent was obtained from all study participants.
Gene and variant annotation. Variants were annotated with information from
Ensembl release 70 using Variant Effect Predictor (VEP) version 2.8 (refs 52,53).
Association testing. To test for association between sequence variants and
disease, we applied logistic regression using disease status as the response and
genotype counts as covariates as we described previously16. The following
individual characteristics that correlate with disease status were also included in the
model as nuisance variables: sex, county of birth, current age or age at death
(ﬁrst- and second-order terms included), blood sample availability for the
individual and an indicator function for the overlap of the lifetime of the individual
with the timespan of phenotype collection.
As described previously16, given genotype counts for n individuals,
g1; g2; . . . ; gn 2 0; 1; 2f g, their phenotypes y1; y2; . . . ; yn 2 0; 1f g and a list of
vectors of nuisance parameters x1; x2; . . . ; xn , the logistic regression model
states that
Li a; b; gð Þ ¼ P yi ¼ 1 j gi; xið Þ
logit P yi ¼ 1 j gi; xið Þð Þ ¼ aþ bgiþ gTxi; for all i 2 1; 2; . . . ; nf g;
where a, b and g are the regression coefﬁcients and Li is the contribution of the ith
indivual to the likelihood function; L a; b; gð Þ ¼Qni¼1 Li a;b; gð Þ. It is then possible
to test for association based on the asymptotic assumption that the likelihood ratio
statistic follows a w2 distribution with one degree of freedom:
2 log
max
a;b;g
L a; b; gð Þ
max
a;g
L a; b ¼ 0; gð Þ
0
@
1
A  w21:
Given the computation cost of maximizing over the nuisance parameters for every
marker in the genome, the likelihood was maximized under the null hypothesis of
b¼ 0, which is the same for all markers, and use the maximizer of g, ~g, under the
alternative. This methods leads to a smaller likelihood ratio than maximizing over g
for every marker because maxa;b;g L a;b; gð Þ  maxa;b L a; b; g ¼ ~gð Þ.
Our analysis is based on imputed genotype values where the values of gi are not
known. Instead, we use P(gi¼ j|Ii) for jA{0,1,2}, where Ii stands for the information
about gi. Given the logistic regression model above, this allows us to calculate
P yi ¼ 1 j Iið Þ ¼
X2
j¼0
P gi ¼ j j Iið Þ P yi ¼ 1 j gið Þ; for all i 2 1; 2; . . . ; nf g:
Testing quantitative traits. To test for association between quantitative traits and
sequence variants a generalized form of linear regression was used as described
previously16. Let y be a vector of quantitative measurements, and let g be a vector of
expected allele counts for the tested variant. Assuming the quantitative
measurements follow a normal distribution with a mean that depends linearly on
the expected allele at the variant and a variance covariance matrix proportional to
the kinship matrix:
y  N aþbg; 2s2F ;
where
Fij
¼ 12 ; i ¼ j
2kij; i 6¼ j

:
is the kinship matrix as estimated from the Icelandic genealogical database. We
split individuals with trait values into smaller clusters for the calculation as it is not
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computationally feasible to use the full model. The maximum likelihood estimates
for the parameters a, b and s (ref. 2) involve inverting the kinship matrix. If
there are n individuals in the cluster, then this inversion requires O(n3)
calculations. However, because these calculations only need to be performed once,
the computational cost of doing a genome-wide association scan will only be O(n2)
calculations per variant, which is the cost of calculating the maximum likelihood
estimates if the kinship matrix has already been inverted. The ALP measurements
from the Danish Inter99 (ref. 54) study were tested using a generalized log-linear
regression, assuming an additive genetic model, for association with allele count of
rs34605986 using the R software package.
Adjusting for relatedness. Relatedness and stratiﬁcation within the sample sets
were accounted for as we previously described16 using the genomic control
method55. P values were adjusted by dividing the corresponding w2 value with an
inﬂation factor lg estimated based on a set of about 300,000 common variants
distributed across the genome
Inheritance models in association testing. The sum of the two imputed
haplotype probabilities was used as a covariate for both the logistic regression and
the generalized linear regression when testing for association under the additive
model16. Where an individual was imputed to have the minor allele of a sequence
variant with probability af on his paternal chromosome and am on his maternal
chromosome, then afþ am was used as a covariate.
Conditional analysis. When testing a variant conditioning on the expected
genotypes of another variant the analysis was carried out using the same software
used in the GWAS analysis19.
Gene expression speciﬁcity classiﬁcation. Genes were deﬁned to have tissue-
speciﬁc or tissue-enriched gene expression as described by Fagerberg et al.31
(ArrayExpress: E-MTABB-1773). Brieﬂy, tissue-speciﬁc expression is deﬁned as at
least 50-fold higher FPKM (fragments per kilobase of exon per million fragments
mapped) than all other tissues (N¼ 27) and tissue-enriched expression is deﬁned
as at least ﬁvefold higher FPKM than all other tissues.
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